U.S. License Holder:
Pfizer Inc.
Date of License:
October-11-2024
Last Update:
Oct-15-2024
FDA-Approved Indications
FDA-Approved Label Not Yet Available. HYMPAVZI (marstacimab-hncq) is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.